Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver.

[1]  P. Stewart,et al.  Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo , 2008, Proceedings of the National Academy of Sciences.

[2]  C. Napoli,et al.  Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer , 2008, Cell.

[3]  L. Work,et al.  Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  N. D. Di Paolo,et al.  The influence of blood on in vivo adenovirus bio-distribution and transduction. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  M. Havenga,et al.  Targeting of Adenovirus Serotype 5 (Ad5) and 5/47 Pseudotyped Vectors In Vivo: Fundamental Involvement of Coagulation Factors and Redundancy of CAR Binding by Ad5 , 2007, Journal of Virology.

[6]  S. Holbeck,et al.  Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  G. Guillon,et al.  Remodelling of calcium signalling during liver regeneration in the rat. , 2007, Journal of hepatology.

[8]  H. Mizuguchi,et al.  Fiber-Modified Adenovirus Vectors Decrease Liver Toxicity through Reduced IL-6 Production1 , 2007, The Journal of Immunology.

[9]  M. Havenga,et al.  Influence of Coagulation Factor Zymogens on the Infectivity of Adenoviruses Pseudotyped with Fibers from Subgroup D , 2007, Journal of Virology.

[10]  A. Parker,et al.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. , 2006, Blood.

[11]  R. Alemany,et al.  Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. , 2006, The Journal of general virology.

[12]  L. Pastore,et al.  Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors , 2006, Gene Therapy.

[13]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[14]  D. Collen,et al.  Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. , 2005, Human gene therapy.

[15]  J. Mathis,et al.  A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy , 2005, Gene Therapy.

[16]  J. Bergelson,et al.  Adenovirus Receptors , 2005, Journal of Virology.

[17]  Stuart A Nicklin,et al.  The influence of adenovirus fiber structure and function on vector development for gene therapy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  A. Gaggar,et al.  Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity , 2005, Journal of Virology.

[19]  J. Bergelson,et al.  CAR: a virus receptor within the tight junction. , 2005, Advanced drug delivery reviews.

[20]  D. Curiel,et al.  Identification of Sites in Adenovirus Hexon for Foreign Peptide Incorporation , 2005, Journal of Virology.

[21]  K. Zinn,et al.  Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus , 2004, Gene Therapy.

[22]  U. Greber,et al.  Adenovirus endocytosis , 2004, The journal of gene medicine.

[23]  Yong Wang,et al.  Systemic dissemination of viral vectors during intratumoral injection. , 2003, Molecular cancer therapeutics.

[24]  H. Mizuguchi,et al.  Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  A. Gaggar,et al.  CD46 is a cellular receptor for group B adenoviruses , 2003, Nature Medicine.

[26]  M. Perricaudet,et al.  Simultaneous CAR- and αV integrin-binding ablation fails to reduce Ad5 liver tropism , 2003 .

[27]  G. Nemerow,et al.  Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. , 2003, Human Gene Therapy.

[28]  H. Hamada,et al.  Reduction of Natural Adenovirus Tropism to the Liver by both Ablation of Fiber-Coxsackievirus and Adenovirus Receptor Interaction and Use of Replaceable Short Fiber , 2003, Journal of Virology.

[29]  P. Roelvink,et al.  Advances towards targetable adenovirus vectors for gene therapy. , 2002, Current opinion in molecular therapeutics.

[30]  M. Rollence,et al.  In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  M. Fornerod,et al.  Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1 , 2001, Nature Cell Biology.

[32]  R. Alemany,et al.  Blood clearance rates of adenovirus type 5 in mice. , 2000, The Journal of general virology.

[33]  F. Blanche,et al.  An improved anion-exchange HPLC method for the detection and purification of adenoviral particles , 2000, Gene Therapy.

[34]  V. Krasnykh,et al.  Genetic targeting of adenoviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  G. Nemerow,et al.  Adenovirus Vector Pseudotyping in Fiber-Expressing Cell Lines: Improved Transduction of Epstein-Barr Virus-Transformed B Cells , 2000, Journal of Virology.

[36]  M. Perricaudet,et al.  RGD Inclusion in the Hexon Monomer Provides Adenovirus Type 5-Based Vectors with a Fiber Knob-Independent Pathway for Infection , 1999, Journal of Virology.

[37]  I. Kovesdi,et al.  Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. , 1995, Gene therapy.

[38]  S. Kochanek,et al.  Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  M. Perricaudet,et al.  Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation , 2003, Gene Therapy.